University Of Leeds

Genetics largely influence fussy eating in children, with 60% variation at 16 months rising to 74% by adolescence, according to a twins study. Environmental factors, like family meal habits, are significant in toddlerhood, suggesting early interventions for varied diets may be most effective.

The FDA granted fast track designation to MM-II, a non-opioid product for osteoarthritis knee pain, following a phase 2b trial showing significant pain relief for up to 26 weeks. This designation aims to expedite the development and review of MM-II, potentially offering a new treatment option for OA patients.

Scientists developed artificial sugars to improve disease diagnosis and treatment, using enzymes and chemical synthesis to create 150 modified sugars with fluorine atoms, enhancing specificity and stability for diagnostics and potential drug discovery.

AVA6000 demonstrates safety and efficacy in FAP-positive solid tumors, with durable RECIST responses and reduced cardiac toxicity compared to conventional doxorubicin. The pre|CISION-enabled doxorubicin shows altered pharmacokinetics, suggesting improved tumor targeting and reduced systemic side effects.

Scientists developed fluoro-sugars for diagnostics and therapeutics, showing potential in detecting bacterial toxins via lateral flow technology, and offering alternatives to antibodies in low-cost, heat-stable diagnostics.

The London Biotechnology Show (18-19 June 2025) is set to surpass its debut success with a 4000 sqm floor plan, featuring 70+ exhibitors and 60+ speakers from leading companies like Google, Microsoft, and Novo Nordisk. Highlights include the Hosted Buyer Programme and a comprehensive conference on biotechnology trends, including gene editing and regenerative medicine.

Avacta Group to present updated Phase 1a trial data of AVA6000 at 2024 ESMO Congress in Barcelona, focusing on FAP-positive solid tumours. AVA6000 is a doxorubicin peptide drug conjugate targeting the tumour microenvironment.

U.K. government proposes workers' right to request a four-day workweek, but critics argue it may benefit only well-paid workers, with longer days potentially undermining benefits and health. The proposal raises questions about its purpose and potential, suggesting the need for policy changes to address low wages and support public sector trials, aiming for a 2040 target.

NAPIC aims to drive UK's alternative protein sector innovation, supporting plant-based proteins, lab-grown meats, and protein-rich algae. With £15m funding, it unites businesses, researchers, and stakeholders to address food security and sustainability challenges, potentially creating 25,000 jobs by 2035.

Crestone announces positive Phase 2 trial results for CRS3123 in treating C. difficile infections, showing high clinical cure rates, low recurrence, and safety. NIAID funds $4.5 million for further studies.